Active Awards Portfolio Dashboard
It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.
Filter Awards
| Disease |
Cell Type |
Therapeutic or Technology | Institution | Stage | Project Objective | Details |
|---|---|---|---|---|---|---|
| HIV/AIDS | Personalized cell therapy | COH |
 |
IND | ||
| Retinitis Pigmentosa | Therapeutic Approach | jCyte |
 |
Clinical Trial, Phase 2 | ||
| Corneal Damage | Adult Stem Cell | Personalized cell therapy | UCLA |
 |
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Blood Disorders, Immune Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
 |
Proof of Concept | |
| Amyotrophic Lateral Sclerosis | Adult Stem Cell | Personalized cell therapy | BrainStorm |
 |
Clinical Trial, Phase 3 | |
|
HIV/AIDS, Immune Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| HIV/AIDS | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Development Candidate, Proof of Concept | |
|
Beta Thalassemia, Sickle Cell Disease |
Adult Stem Cell | Diagnostic Test | UCSF |
 |
Regulated Lab Test, Ready for Validation | |
|
HIV-related Lymphoma, HIV/AIDS |
Adult Stem Cell | Gene-modified, personalized cell therapy | UC Davis |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| COVID-19 | Adult Stem Cell | Small molecule therapy | Stanford |
|
Development Candidate, Proof of Concept | |
| Blood Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | Angiocrine |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Bone or Cartilage Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | Rocket Pharmaceuticals, Inc. |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Spinal Cord Injury | Adult Stem Cell | Donor cell therapy | UC Irvine |
|
Development Candidate | |
|
Heart Disease, Danon Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSD |
|
Development Candidate, Proof of Concept | |
| Kidney Failure | Adult Stem Cell | Donor cell therapy | Stanford |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Hyper IgM Syndrome, Immune Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Pre-IND/IDE or Equivalent | |
|
Immune Disease, X-linked Chronic Granulomatous Disease |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| COVID-19 | Adult Stem Cell | Vaccine | Stanford |
|
Development Candidate, Proof of Concept | |
| Spina Bifida | Adult Stem Cell | Donor cell therapy | UC Davis |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Kidney Failure | Adult Stem Cell | Donor cell therapy | Medeor Therapeutics |
|
Clinical Trial, Phase 3 | |
| Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | UCLA |
|
Development Candidate, Proof of Concept | |
| Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
|
IND | |
| Ovarian Cancer | Adult Stem Cell | Gene-modified, donor cell therapy | COH |
|
Pre-IND/IDE or Equivalent | |
| COVID-19 | Adult Stem Cell | Gene-modified, donor cell therapy | COH |
|
Development Candidate, Proof of Concept | |
| Sickle Cell Disease | Adult Stem Cell | Donor cell therapy | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Sarcoma | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Multiple Myeloma | Adult Stem Cell | Personalized cell therapy | UCLA |
|
Pre-IND/IDE or Equivalent | |
| COVID-19 | Adult Stem Cell | Vaccine | UCLA |
|
Development Candidate, Proof of Concept | |
| Brain Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Blood Disorders | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Development Candidate, Proof of Concept | |
| Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) | Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Immune Disease, Leukocyte Adhesion Deficiency |
Adult Stem Cell | Gene-modified, personalized cell therapy | Rocket Pharmaceuticals, Inc. |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Leukemia, Acute Myeloid (AML), Multiple Myeloma |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Pre-IND/IDE or Equivalent | |
| COVID-19 | Adult Stem Cell | Small molecule therapy | UCLA |
|
Pre-IND/IDE or Equivalent | |
|
Arthritis, Osteoarthritis |
Adult Stem Cell | Small molecule therapy | Calibr |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
B cell cancers, Leukemia |
Adult Stem Cell | Gene-modified, personalized cell therapy | Stanford |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Type 1 diabetes | Adult Stem Cell | Donor cell therapy | UCSF |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Pulmonary Hypertension, Vascular Disease |
Adult Stem Cell | Donor cell therapy | Cedars-Sinai |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
COVID-19, Respiratory Disorders |
Adult Stem Cell | Donor cell therapy | Celularity Inc |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Blood Cancer, Bone Marrow Transplant and Viral Infection |
Adult Stem Cell | Donor cell therapy | CHLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Inflammatory bowel disease | Adult Stem Cell | Donor cell therapy | Vitabolus, Inc. |
|
Development Candidate, Proof of Concept | |
| Beta Thalassemia | Adult Stem Cell | Gene-modified, personalized cell therapy | Sangamo |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Cystinosis, Kidney Failure |
Adult Stem Cell | Gene-modified, personalized cell therapy | UCSD |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Sickle Cell Disease | Adult Stem Cell | Gene-modified, personalized cell therapy | UCSF |
|
Pre-IND/IDE or Equivalent | |
| Multiple Myeloma | Adult Stem Cell | Gene-modified, personalized cell therapy | Poseida Therapeutics |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
|
Immune Disease, Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Adult Stem Cell | Gene-modified, personalized cell therapy | Orchard Therapeutics |
|
Clinical Trial, Phase 2 | |
|
Brain Cancer, Breast Cancer |
Adult Stem Cell | Gene-modified, personalized cell therapy | COH |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Kidney Failure | Adult Stem Cell | Donor cell therapy | Stanford |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Lung Cancer | Adult Stem Cell | Gene-modified, personalized cell therapy | UCLA |
|
Clinical Trial, Phase 1 or Phase 1/2 | |
| Vascular Disease | Adult Stem Cell | Biologic | UCSD |
|
Pre-IND/IDE or Equivalent |
Pages
